Prescription drug monitoring programs: Assessing the association between “best practices” and opioid use in Medicare

Moyo, Patience; Simoni, Jane M.; Griffin, Beth Ann; Harrington, Donna; Alexander, G. Caleb; Palumbo, Francis B.; Onukwugha, Eberechukwu

doi:10.1111/1475-6773.13197

Cited by 11 publications

(7 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A summary of the identified intervention studies is presented in Table 15. [117][118][119][120][121][122][123][124][125][126][127][128][129][130][131][132][133] The descriptions are organized by topic (or purpose) of the interventions, by level of the intervention (screening, patient, clinician, and healthcare system), then by study. Appendix D Tables D-4 to D-6 include further details of each study.…”

Section: Overview Of Literaturementioning

confidence: 99%

Prevention, Diagnosis, and Management of Opioids, Opioid Misuse, and Opioid Use Disorder in Older Adults

Zullo¹,

Danko²,

Moyo³

et al. 2020

Self Cite

View full text Add to dashboard Cite

None of the investigators have any affiliations or financial involvement that conflicts with the material presented in this report.The information in this report is intended to help healthcare decision makers-patients and clinicians, health system leaders, and policymakers, among others-make well-informed decisions and thereby improve the quality of healthcare services. This report is not intended to be a substitute for the application of clinical judgment. Anyone who makes decisions concerning the provision of clinical care should consider this report in the same way as any medical reference and in conjunction with all other pertinent information, i.e., in the context of available resources and circumstances presented by individual patients.This report is made available to the public under the terms of a licensing agreement between the author and the Agency for Healthcare Research and Quality. This report may be used and reprinted without permission except those copyrighted materials that are clearly noted in the report. Further reproduction of those copyrighted materials is prohibited without the express permission of copyright holders. AHRQ or U.S. Department of Health and Human Services endorsement of any derivative products that may be developed from this report, such as clinical practice guidelines, other quality enhancement tools, or reimbursement or coverage policies may not be stated or implied.AHRQ appreciates appropriate acknowledgment and citation of its work.

show abstract

Section: Overview Of Literaturementioning

confidence: 99%

Prevention, Diagnosis, and Management of Opioids, Opioid Misuse, and Opioid Use Disorder in Older Adults

Zullo¹,

Danko²,

Moyo³

et al. 2020

Self Cite

View full text Add to dashboard Cite

show abstract

“…Overall, half of the studies involved patients [9,18,22–24,26,27,32,34,36–38,41–43,45,46,48,50,53,54,59,62,63,65,66,71,73,75,77–80,84–86,88,90,93,95,97,98,100,101,104,105,108–110,115–118,121,123,125,130,131,134,140,144,146,147,149,151,152,154–156,158,159,161,163,165,167] and 47% included health‐care providers [11,19,20,25,29,30,33,35,37,39,40,43,44,49,51,54–61,67–69,71,72,74,76,80–83,87,91,93,94,96,102,103,106,111–114,119,120,122,124,125,127,128,130,132,133,136–139,141,143,145,147,148,150,153,157,160,162,165]. Some studies included both patient and provider populations [36, 37, 54, 59, 80, 93, 130, 147, 166].…”

Section: Resultsmentioning

confidence: 99%

“…The extracted data from the included studies were then classified into main conceptual categories and summarised to align with the scoping review objective and research questions. The data extraction results are presented in Tables S1 and S2 [18–166], Supporting Information.…”

Section: Resultsmentioning

confidence: 99%

Mapping the research addressing prescription drug monitoring programs: A scoping review

Hoppe

Karimi

Khalil

2022

Drug and Alcohol Review

View full text Add to dashboard Cite

Issues. Prescription drug monitoring programs are a harm minimisation intervention and clinical decision support tool that address the public health concern surrounding prescription drug misuse. Given the large number of studies published to date and the ongoing implementation of these programs, it is important to map the literature and identify areas for further research to improve practice. Approach. A scoping review was undertaken to identify the research on prescription drug monitoring programs published between January 2015 and April 2021. Key Findings. A total of 153 citations were included in this scoping review. The majority of the studies originated from the USA and were quantitative. Results on program effectiveness are mixed and mainly examine their association with opioid-related outcomes. Unintended consequences are revealed in the literature and this review also highlights barriers to program use. Implications. Overall, findings are mixed despite the large number of studies published to date. Mapping the literature identifies priority areas for further research that can advise policymakers and clinicians on practice improvement. Conclusion. Results on prescription drug monitoring program effectiveness are mixed and mainly examine their association with opioid-related outcomes. This review highlights barriers to prescription drug monitoring program effectiveness related to program use and system integration. Further research is needed in these areas to improve prescription drug monitoring program use and patient outcomes.

show abstract

“…[94][95][96][97][98][99] ThesepositivefindingsonstrongPDMPswere notuniform:1studyfoundnosignificantassociationbetween mandatory use requirements and the number of opioid prescriptions among patients undergoing general surgical procedures 100 and another study found that strong and weak PDMPs were associated with similar changes in opioid prescription rates, the number of cumulative doses, and prescriptionlength(indays)amongMedicarebeneficiaries. 101 Studies published after our review period investigated GoodSamaritanlaws,painclinicandmarijuanaregulations, prescribing guidelines, and educational interventions. Evidence in more recent studies refutes positive findings from the studies in our review.…”

Section: Discussionmentioning

confidence: 99%

A Rapid Review of the Impact of Systems-Level Policies and Interventions on Population-Level Outcomes Related to the Opioid Epidemic, United States and Canada, 2014-2018

et al. 2020

View full text Add to dashboard Cite

Objectives In the United States, rising rates of overdose deaths and recent outbreaks of hepatitis C virus and HIV infection are associated with injection drug use. We updated a 2014 review of systems-level opioid policy interventions by focusing on evidence published during 2014-2018 and new and expanded opioid policies. Methods We searched the MEDLINE database, consistent with the 2014 review. We included articles that provided original empirical evidence on the effects of systems-level interventions on opioid use, overdose, or death; were from the United States or Canada; had a clear comparison group; and were published from January 1, 2014, through July 19, 2018. Two raters screened articles and extracted full-text data for qualitative synthesis of consistent or contradictory findings across studies. Given the rapidly evolving field, the review was supplemented with a search of additional articles through November 17, 2019, to assess consistency of more recent findings. Results The keyword search yielded 535 studies, 66 of which met inclusion criteria. The most studied interventions were prescription drug monitoring programs (PDMPs) (59.1%), and the least studied interventions were clinical guideline changes (7.6%). The most common outcome was opioid use (77.3%). Few articles evaluated combination interventions (18.2%). Study findings included the following: PDMP effectiveness depends on policy design, with robust PDMPs needed for impact; health insurer and pharmacy benefit management strategies, pill-mill laws, pain clinic regulations, and patient/health care provider educational interventions reduced inappropriate prescribing; and marijuana laws led to a decrease in adverse opioid-related outcomes. Naloxone distribution programs were understudied, and evidence of their effectiveness was mixed. In the evidence published after our search’s 4-year window, findings on opioid guidelines and education were consistent and findings for other policies differed. Conclusions Although robust PDMPs and marijuana laws are promising, they do not target all outcomes, and multipronged interventions are needed. Future research should address marijuana laws, harm-reduction interventions, health insurer policies, patient/health care provider education, and the effects of simultaneous interventions on opioid-related outcomes.

show abstract

Prescription drug monitoring programs: Assessing the association between “best practices” and opioid use in Medicare

Cited by 11 publications

References 44 publications

Prevention, Diagnosis, and Management of Opioids, Opioid Misuse, and Opioid Use Disorder in Older Adults

Prevention, Diagnosis, and Management of Opioids, Opioid Misuse, and Opioid Use Disorder in Older Adults

Mapping the research addressing prescription drug monitoring programs: A scoping review

A Rapid Review of the Impact of Systems-Level Policies and Interventions on Population-Level Outcomes Related to the Opioid Epidemic, United States and Canada, 2014-2018

Contact Info

Product

Resources

About